Artivion (AORT) Scheduled to Post Earnings on Monday

Artivion (NYSE:AORT) is scheduled to release its earnings data after the market closes on Monday, May 6th. Analysts expect Artivion to post earnings of $0.02 per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, February 15th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of ($0.13) by $0.24. The firm had revenue of $93.67 million during the quarter, compared to analysts’ expectations of $89.75 million. Artivion had a positive return on equity of 3.02% and a negative net margin of 8.67%. On average, analysts expect Artivion to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Artivion Stock Performance

NYSE AORT opened at $20.93 on Friday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.43 and a current ratio of 4.85. The stock’s fifty day moving average is $20.38 and its two-hundred day moving average is $17.97. The firm has a market capitalization of $862.32 million, a P/E ratio of -27.91 and a beta of 1.66. Artivion has a fifty-two week low of $12.16 and a fifty-two week high of $21.90.

Insiders Place Their Bets

In other news, SVP Marshall S. Stanton sold 2,183 shares of the company’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $20.39, for a total value of $44,511.37. Following the transaction, the senior vice president now owns 83,296 shares of the company’s stock, valued at approximately $1,698,405.44. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CAO Amy Horton sold 1,695 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $18.86, for a total transaction of $31,967.70. Following the completion of the transaction, the chief accounting officer now owns 122,345 shares of the company’s stock, valued at approximately $2,307,426.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Marshall S. Stanton sold 2,183 shares of Artivion stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $20.39, for a total transaction of $44,511.37. Following the completion of the sale, the senior vice president now owns 83,296 shares of the company’s stock, valued at approximately $1,698,405.44. The disclosure for this sale can be found here. Insiders sold a total of 149,952 shares of company stock valued at $2,891,627 over the last quarter. 8.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $25.00 price objective on shares of Artivion in a report on Monday, April 8th. Stifel Nicolaus increased their price target on shares of Artivion from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, February 16th.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.